BioSpace News Archive

Sensient Technologies Corporation (NYSE: SXT) reported consolidated revenue of $371.7 million in this year’s second quarter compared to $335.8 million in last year’s second quarter.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global fiber fortified beverages market accounts for a total valuation of US$ 6.98 billion and is anticipated to attain an estimated revenue total of US$ 12.1 billion by the end of 2032.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Dental restoration is an integrated management of oral health that involves restoration of mouth to an esthetic and functional state.

The global breast pads market is anticipated to witness exponential growth during the forecast period of 2021-2031 owing to the increasing awareness of the use of breast pads among the global populace.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Hormones released by thyroid gland play a crucial role in stimulating metabolism, growth, and calories processing.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global portable medical electronic products market is expected to witness strong growth during the forecast period between 2021 and 2031.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global obesity surgery devices market is expected to witness strong growth during the forecast period between 2021 and 2031.

Aurinia Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending voclosporin for marketing authorization to treat adults with active lupus nephritis, a serious complication of systemic lupus erythematosus.

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase 1b/2a clinical trial of SON-080 has been authorized to begin.

BioElectronics Corporation announced via a Shareholder’s update that the Company has completed and undertaken additional clinical research and has received the initial stocking purchase order from its distribution partner, Stada.